AMRX vs JAZZ
AMRX: A diversified biopharmaceutical company providing a broad range of generic, branded, and specialty medicines alongside pharmaceutical distribution services. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | AMRX | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $18.32 | $252.86 | |
| Market cap as of 2026-08-03 | $5.8B | $15.9B | |
| P/E as of 2026-08-03 | 49.12 | 538.57 | AMRX lower |
| PEG as of 2026-08-03 | 2.85 | 65.11 | AMRX lower |
| Net margin as of 2026-08-03 | +4.0% | +0.7% | AMRX higher |
| Gross margin as of 2026-08-03 | +38.7% | +88.0% | JAZZ higher |
| Operating margin as of 2026-08-03 | +14.3% | -0.8% | AMRX higher |
| ROE as of 2026-08-03 | -34.9% | +0.7% | JAZZ higher |
| ROA as of 2026-08-03 | +3.4% | +0.3% | AMRX higher |
| Debt / equity as of 2026-08-03 | 136.58 | 1.18 | JAZZ lower |
| Revenue growth (YoY) as of 2026-08-03 | +7.6% | +9.2% | JAZZ higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +5.3% | AMRX higher |
| Beta as of 2026-08-03 | 0.88 | 0.71 | |
| 1-year return as of 2026-07-31 close | +134.3% | +120.6% | AMRX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.